Predictive Factors of Survival in Patients Treated with Definitive Chemoradiotherapy for Squamous Cell Esophageal Carcinoma

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2006 Jul 11

PMID 16830371

Citations 33

Authors

Frederic Di Fiore

Stephane Lecleire

Olivier Rigal

Marie-Pierre Galais

Emmanuel Ben Soussan

Isabelle David

Bernard Paillot

Jacques-Henri Jacob

Pierre Michel

Affiliations

Soon will be listed here.

Abstract

Aim: The aim of the study was to evaluate the predictive factors of survival in patients with locally advanced squamous cell esophageal carcinoma (LASCOC) treated with definitive chemoradiotherapy (CRT) regimen based on the 5FU/CDDP combination.

Methods: All patients with LASCOC treated with a definitive CRT using the 5FU/CDDP combination between 1994 and 2000 were retrospectively included. Clinical complete response (CCR) to CRT was assessed by esophageal endoscopy and CT-scan 2 mo after CRT completion. Prognostic factors of survival were assessed using univariate and multivariate analysis by the Cox regression model.

Results: A total of 116 patients were included in the study. A CCR to CRT was observed in 86/116 (74.1%). The median survival was 20 mo (range 2-114) and the 5-year survival was 9.4%. Median survival of responder patients to CRT was 25 mo (range 3-114) as compared to 9 mo (range 2-81) in non-responder patients (P < 0.001). In univariate analysis, survival was associated with CCR (P < 0.001), WHO performance status < 2 (P = 0.01), tumour length < 6 cm (P = 0.045) and weight loss < 10% was in limit of significance (P = 0.053). In multivariate analysis, survival was dependant to CCR (P < 0.0001), weight loss < 10% (P = 0.034) and WHO performance < 2 (P = 0.046).

Conclusion: Our results suggest that survival in patients with LASCOC treated with definitive CRT was correlated to CCR, weight loss and WHO performance status.

Citing Articles

Impacts of sarcopenia on adverse events and prognosis in Chinese patients with esophageal cancer undergoing chemoradiotherapy.

Qu J, Liu Y, Yuan Y, Yu Z, Ding J, He Z Front Nutr. 2025; 12:1523674.

PMID: 40051963 PMC: 11882421. DOI: 10.3389/fnut.2025.1523674.

The prognostic value of the controlling nutritional status (CONUT) score in predicting outcomes of esophageal cancer patients receiving radiotherapy with or without chemotherapy.

Chang L, Zhang X, Li Q Transl Cancer Res. 2024; 12(12):3618-3628.

PMID: 38197080 PMC: 10774058. DOI: 10.21037/tcr-23-1193.

Impact of Weight Loss on Patients with Locally Advanced Esophageal and Esophagogastric Junction Cancers Treated with Chemoradiotherapy.

Wiwitkeyoonwong J, Jiarpinitnun C, Hiranyatheb P, Ngamphaiboon N Asian Pac J Cancer Prev. 2021; 22(12):3847-3855.

PMID: 34967563 PMC: 9080349. DOI: 10.31557/APJCP.2021.22.12.3847.

Survival Status of Esophageal Cancer Patients and its Determinants in Ethiopia: A Facility Based Retrospective Cohort Study.

Hassen H, Teka M, Addisse A Front Oncol. 2021; 10:594342.

PMID: 33659206 PMC: 7917207. DOI: 10.3389/fonc.2020.594342.

Outcomes of Definitive Chemoradiotherapy for Stage IVa (T4b vs. N4) Esophageal Squamous Cell Carcinoma Based on the Japanese Classification System: A Retrospective Single-Center Study.

Wada Y, Anbai A, Takagi N, Kumagai S, Okuyama E, Nanjo H Cancers (Basel). 2020; 13(1).

PMID: 33375169 PMC: 7792968. DOI: 10.3390/cancers13010008.

References

Murakami M, Kuroda Y, Okamoto Y, Kono K, Yoden E, Kusumi F . Neoadjuvant concurrent chemoradiotherapy followed by definitive high-dose radiotherapy or surgery for operable thoracic esophageal carcinoma. Int J Radiat Oncol Biol Phys. 1998; 40(5):1049-59. DOI: 10.1016/s0360-3016(97)00900-0. View

Berger A, Farma J, Scott W, Freedman G, Weiner L, Cheng J . Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol. 2005; 23(19):4330-7. DOI: 10.1200/JCO.2005.05.017. View

Wu L, Wang B, Feng J, Cheng W, Liu G, Xu X . Preoperative TN staging of esophageal cancer: comparison of miniprobe ultrasonography, spiral CT and MRI. World J Gastroenterol. 2003; 9(2):219-24. PMC: 4611315. DOI: 10.3748/wjg.v9.i2.219. View

Tahara M, Ohtsu A, Hironaka S, Boku N, Ishikura S, Miyata Y . Clinical impact of criteria for complete response (CR) of primary site to treatment of esophageal cancer. Jpn J Clin Oncol. 2005; 35(6):316-23. DOI: 10.1093/jjco/hyi095. View

Leichman L, Herskovic A, Leichman C, Lattin P, STEIGER Z, Tapazoglou E . Nonoperative therapy for squamous-cell cancer of the esophagus. J Clin Oncol. 1987; 5(3):365-70. DOI: 10.1200/JCO.1987.5.3.365. View

Menegoz F, Black R, Arveux P, Magne V, Ferlay J, Buemi A . Cancer incidence and mortality in France in 1975-95. Eur J Cancer Prev. 1998; 6(5):442-66. DOI: 10.1097/00008469-199710000-00005. View

Seitz J, Milan C, Giovannini M, Dumas F, Cauvin J, Conroy T . [Concurrent concentrated radio-chemotherapy of epidermoid cancer of the esophagus. Long-term results of a phase II national multicenter trial in 122 non-operable patients (FFCD 8803)]. Gastroenterol Clin Biol. 2003; 24(2):201-10. View

Lim J, Truong P, Berthelet E, Pai H, Joe H, Wai E . Endoscopic response predicts for survival and organ preservation after primary chemoradiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2003; 57(5):1328-35. DOI: 10.1016/s0360-3016(03)00751-x. View

Forastiere A, Orringer M, Urba S, Zahurak M . Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus: final report. J Clin Oncol. 1993; 11(6):1118-23. DOI: 10.1200/JCO.1993.11.6.1118. View

10.

Cooper J, Guo M, Herskovic A, Macdonald J, Martenson Jr J, Al-Sarraf M . Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA. 1999; 281(17):1623-7. DOI: 10.1001/jama.281.17.1623. View

11.

Thomas Jr C, Berkey B, Minsky B, Gaspar L, Herskovic A, Rich T . Recursive partitioning analysis of pretreatment variables of 416 patients with locoregional esophageal cancer treated with definitive concomitant chemoradiotherapy on Intergroup and Radiation Therapy Oncology Group trials. Int J Radiat Oncol Biol Phys. 2004; 58(5):1405-10. DOI: 10.1016/j.ijrobp.2003.09.022. View

12.

Rice T . Clinical staging of esophageal carcinoma. CT, EUS, and PET. Chest Surg Clin N Am. 2000; 10(3):471-85. View

13.

Terry P, Lagergren J, Ye W, Nyren O, Wolk A . Antioxidants and cancers of the esophagus and gastric cardia. Int J Cancer. 2000; 87(5):750-4. View

14.

Burmeister B, Denham J, OBrien M, Jamieson G, Gill P, Devitt P . Combined modality therapy for esophageal carcinoma: preliminary results from a large Australasian multicenter study. Int J Radiat Oncol Biol Phys. 1995; 32(4):997-1006. DOI: 10.1016/0360-3016(94)00449-u. View

15.

Herskovic A, Martz K, Al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V . Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992; 326(24):1593-8. DOI: 10.1056/NEJM199206113262403. View

16.

Ohtsu A, Boku N, Muro K, Chin K, Muto M, Yoshida S . Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol. 1999; 17(9):2915-21. DOI: 10.1200/JCO.1999.17.9.2915. View

17.

Hironaka S, Ohtsu A, Boku N, Muto M, Nagashima F, Saito H . Nonrandomized comparison between definitive chemoradiotherapy and radical surgery in patients with T(2-3)N(any) M(0) squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys. 2003; 57(2):425-33. DOI: 10.1016/s0360-3016(03)00585-6. View

18.

Fujita H, Sueyoshi S, Tanaka T, Tanaka Y, Sasahara H, Shirouzu K . Prospective non-randomized trial comparing esophagectomy-followed-by-chemoradiotherapy versus chemoradiotherapy-followed-by-esophagectomy for T4 esophageal cancers. J Surg Oncol. 2005; 90(4):209-19. DOI: 10.1002/jso.20259. View

19.

Seitz J, Giovannini M, Fuentes P, GIUDICELLI R, GAUTHIER A, Carcassonne Y . Inoperable nonmetastatic squamous cell carcinoma of the esophagus managed by concomitant chemotherapy (5-fluorouracil and cisplatin) and radiation therapy. Cancer. 1990; 66(2):214-9. DOI: 10.1002/1097-0142(19900715)66:2<214::aid-cncr2820660204>3.0.co;2-z. View

20.

Chan A, Wong A . Is combined chemotherapy and radiation therapy equally effective as surgical resection in localized esophageal carcinoma?. Int J Radiat Oncol Biol Phys. 1999; 45(2):265-70. DOI: 10.1016/s0360-3016(99)00199-6. View